Molecular Basis of AmpC Hyperproduction in Clinical Isolates of Escherichia coli | Zendy

E. C. Nelson | Zendy; B. Gay Elisha | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Molecular Basis of AmpC Hyperproduction in Clinical Isolates of Escherichia coli

Author(s) -

E. C. Nelson,

B. Gay Elisha

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.4.957

Subject(s) - escherichia coli , ceftazidime , cefotaxime , biology , ceftriaxone , microbiology and biotechnology , transcription (linguistics) , gene , dna , enterobacteriaceae , promoter , antibiotics , genetics , bacteria , gene expression , pseudomonas aeruginosa , linguistics , philosophy

DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research